

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA

INDIANA PUBLIC RETIREMENT
SYSTEM, Individually and on Behalf
of All Others Similarly Situated,

Plaintiff,

v.

RIVIAN AUTOMOTIVE, INC., *et al.*,

Defendants.

Case No.: 2:24-cv-4566-CBM-JPR

**ORDER RE: DEFENDANTS’
MOTION FOR JUDGMENT ON
THE PLEADINGS**

The matter before the Court is Defendants’ Motion for Judgment on the Pleadings pursuant to Fed. R. Civ. P. 12(c). (Dkt. No. 81 (the “Motion”).)¹

I. BACKGROUND

The operative complaint asserts the following two causes of action: (1) violations of Section 10(b) of the Securities Exchange Act (the “Act”) and Rule 10b-5 against all Defendants; and (2) violations of Section 20(a) of the Act against the Individual Defendants. (Dkt. No. 57 (First Amendment Complaint (“FAC”)).) On August 20, 2025, the Court denied Defendants’ motion to dismiss the FAC for failure to satisfy applicable pleading standards securities claims. (Dkt. No. 76 (the “MTD Order”).) In the Court’s August 20, 2025 MTD Order, the Court found,

¹ After the matter was fully briefed, the parties filed notices of supplemental authority (Dkt. Nos. 84, 88, 89, 90), which the Court has considered in ruling on the instant Motion.

1 *inter alia*, Plaintiffs “sufficiently plead falsity to survive the motion to dismiss
2 stage because the statements created an impression of a state of affairs that
3 differed in a material way from what actually existed,” and “plausibly allege
4 Defendants made positive statements about increases in demand based on the
5 preorder Backlog which was allegedly misleading to investors.” (*Id.* at 5-7.) On
6 September 22, 2025, Defendants filed an answer to the FAC. (Dkt. No. 79.) On
7 October 22, 2025, Defendants filed the instant Motion based on the Ninth
8 Circuit’s decision in *Sneed v. Talphera, Inc.*, 147 F.4th 1123 (9th Cir. 2025),
9 which was issued on August 20, 2025—the same date the Court issued its MTD
10 Order.

11 II. LEGAL STANDARD

12 In ruling on a motion for judgment on the pleadings under Federal Rule of
13 Civil Procedure 12(c), the Court “inquires whether the complaint at issue contains
14 ‘sufficient factual matter, accepted as true, to state a claim of relief that is
15 plausible on its face.’” *Harris v. Cnty. of Orange*, 682 F.3d 1126, 1131 (9th Cir.
16 2012) (quoting *Ashcroft v. Iqbal*, 556 U.S. 662, 678 (2009)). The Court accepts as
17 true all well-pleaded allegations of material fact and construes them in a light most
18 favorable to the non-moving party. *Herrera v. Zumiez, Inc.*, 953 F.3d 1063, 1068
19 (9th Cir. 2020). The Court must also assume as true contents of documents
20 incorporated by reference, and attached to the complaint. *Interpipe Contracting,*
21 *Inc. v. Becerra*, 898 F.3d 879, 887 (9th Cir. 2018); *U.S. v. Ritchie*, 342 F.3d 903,
22 908 (9th Cir. 2003). The Court may also consider facts contained in materials
23 properly the subject of judicial notice. *Heliotrope Gen., Inc. v. Ford Motor Co.*,
24 189 F.3d 971, 981 n.18 (9th Cir. 1999).

25 III. DISCUSSION

26 The FAC alleges Defendants violated Section 10(b) of the Act and Rule
27 10b-5. The elements of a securities fraud action pursuant to Section 10(b) and
28 Rule 10b-5 are: (1) a material misrepresentation or omission of fact, (2) scienter;

(3) a connection with the purchase or sale of a security; (4) transaction and loss causation; and (5) economic loss. *See Zucco Partners*, 552 F.3d at 990; *In re Daou Sys. Inc.*, 411 F.3d 1006, 1014 (9th Cir. 2005). Falsity, scienter, and loss causation must each be pled with particularity. *See Metzler Invest. GMBH*, 540 F.3d at 1061; *Oregon Pub. Employees Ret. Fund*, 774 F.3d at 605. Defendants move for judgment on the pleadings on the ground the Ninth Circuit’s recent decision in *Sneed v. Talphera, Inc.*, 147 F.4th 1123 (9th Cir. 2025), “clarif[ies] the standard for pleading falsity under Section 10(b)” and “is dispositive here” because “[u]nder *Sneed*, no reasonable investor considering Rivian’s disclosures **in their full context**, including the Company’s detailed disclosures about the risks it faced, could have been misled by the challenged statements” because “every one of the five ‘facts’ Plaintiffs allege was concealed by the challenged statements was expressly disclosed to shareholders in statements ignored (or not challenged) by Plaintiffs’ Complaint.” (Motion at 1.) Defendants attach 25 exhibits to the instant Motion (*see* Wiener Decl. Exs. 1-25), which they contend are “on-point disclosures addressing the very issues Plaintiffs allege were concealed,” a reasonable investor would have considered and thus argue a reasonable investor would not have been misled by Defendants’ statements.

In *Sneed v. Talphera, Inc.*, 147 F.4th 1123 (9th Cir. 2025), shareholders brought action against pharmaceutical company, its chief executive officer (CEO), and its chief medical officer (CMO) for securities fraud under § 10(b) of the Act and Rule 10b-5 and for control-person liability based on the pharmaceutical company’s marketing slogan “Tongue and Done” for its under-the-tongue opioid. The United States District Court for the Northern District of California dismissed the shareholders’ complaint for failure to state a claim, and the shareholders appealed. The Ninth Circuit affirmed dismissal, holding the shareholders failed to adequately allege that the company’s slogan “Tongue and Done” would mislead a reasonable investor, reasoning “[t]o decide whether a misstatement or omission

1 can mislead, we need to look at ‘the context surrounding the statement,’ and “[a]
2 reasonable investor would not blindly accept a slogan without considering other
3 information” in the advertising, in a speech at an investor conference, and in SEC
4 disclosures “that clarified the context of ‘Tongue and Done.’” *Id.* at 1127, 1131
5 (citing *Weston Fam. P’ship. LLLP v. Twitter, Inc.*, 29 F.4th 611, 622 (9th Cir.
6 2022)). The Ninth Circuit noted “[c]ontext matters because we presume that a
7 reasonable investor—who has money on the line—acts with care and seeks out
8 relevant information,” and “[a] reasonable investor cares about a statement’s
9 ‘surrounding text, including hedges, disclaimers, and apparently conflicting
10 information.’” *Id.* at 1131 (citing *Sec. Exch. Comm’n v. Monarch Fund*, 608 F.2d
11 938, 942 (2d Cir. 1979); *Omnicare, Inc. v. Laborers Dist. Council Const. Indus.*
12 *Pension Fund*, 575 U.S. 175, 190 (2015)). The Ninth Circuit further noted
13 “[s]ometimes other information outside the immediate document can form the
14 context in which a reasonable investor would view a particular statement,” and
15 “courts sometimes look at falsity through the lens of a ‘total mix’ of information
16 that forms part of the materiality analysis.” *Id.* (citing *In re Oracle Corp. Sec.*
17 *Litig.*, 627 F.3d 376, 390 (9th Cir. 2010) (quoting *In re Convergent Techs. Sec.*
18 *Litig.*, 948 F.2d 507, 512 (9th Cir. 1991))). The Ninth Circuit thus reasoned “a
19 reasonable investor would not blindly accept a marketing slogan by itself when
20 she has access to other contextual information,” “[a] reasonable investor would
21 read ‘Tongue and Done’ in the context of a marketing campaign designed to
22 highlight its key selling point—that patients can receive the drug orally without
23 the frequent redosing required with IV-administered painkillers,” and “a
24 reasonable consumer—who, unlike a reasonable investor, is not presumed to
25 carefully scour all the fine print—understands that a slogan is just that” and
26 “certainly knows not to trust a slogan without investigating further.” *Id.* at 1132.²

27 ² The pharmaceutical company ceased using the “Tongue and Done” slogan after
28 receiving a warning letter from the FDA dated February 11, 2021 wherein the
FDA asserted the company “misbrand[ed] Dsuvia within the meaning of the

1 Plaintiff argues *Sneed* neither created new law, nor a new pleading standard
2 for falsity in securities cases, and therefore cannot be a basis for reconsideration of
3 the Court's MTD Order wherein the Court already found Plaintiff sufficiently pled
4 falsity. Plaintiff argues while the Court's MTD Order did not cite to *Sneed*, the
5 Court already conducted the contextual analysis discussed in *Sneed* in ruling on
6 Defendants' motion to dismiss. Plaintiff argues 24 of the 25 exhibits attached to
7 Defendants' instant Motion which Defendants argue provide the "context" for
8 "contextual review" of the information available to a reasonable investor are the
9 same exhibits previously filed by Defendants for the Court's consideration in
10 connection with Defendants' motion to dismiss. Plaintiff contends the sole new
11 exhibit attached to the instant Motion (Ex. 25) offers no new context because it is
12 duplicative of Exhibit 8. Plaintiff thus argues the "context" information submitted
13 by Defendants in connection with the instant Motion were already considered and
14 rejected by the Court when it ruled on Defendants' motion to dismiss and found
15 that Plaintiff adequately pleaded falsity, and that the Court's MTD Order is the
16 law of the case.

17 *Sneed* was based on an allegedly misleading marketing slogan and is
18 therefore distinguishable based on its facts because the instant case before this
19 Court does not involve an allegedly misleading marketing slogan. *Cf. Sneed*, 147
20 F.4th at 1132. Moreover, *Sneed* did not create new case law or clarify existing
21 case law regarding the pleading standards for falsity in security cases. Rather,
22 *Sneed* cited existing case law in noting that courts should look at the context
23 surrounding the statement in deciding whether a misstatement or omission can be

24 _____
25 Federal Food, Drug and Cosmetic Act [FDCA]" and concluded the company made
26 "false or misleading claims" for purposes of the FDCA by not providing a
27 balanced description of the "risks and benefits" of the drug. *Sneed*, 147 F.4th at
28 1129-30. On appeal, the Ninth Circuit found the FDA's warning letter objecting
to the slogan did not mean the slogan was "not dispositive or even necessarily
probative of falsity claims under the Exchange Act" because "[t]he FDCA
imposes different legal requirements" than the Securities Exchange Act and
"targets a different audience." *Id.* at 1133.

1 misleading. *See Sneed*, 147 F.4th at 1131 (citing cases decided in 1979, 1991,
2 2010, 2015, 2022).

3 Even having considered *Sneed*, the Court cannot find as a matter of law that
4 a reasonable investor would not be misled by Defendants' statements—indeed, the
5 Court considered the context surrounding the alleged statements in denying
6 Defendants' motion to dismiss. This action is based on Defendants' alleged
7 misrepresentation that Rivian was on track to achieve gross margin profits in 2024
8 by increasing the production and sales of its electric vehicles ("EVs"), and
9 Defendants' "repeated[] reassur[ances] [to] the market that Rivian was unscathed
10 by macroeconomic factors impacting the EV industry, which had weakened
11 demand and reduced prices for competitors" when "Rivian was, in fact, suffering
12 from the same macroeconomic factors as its peers," and Rivian had a
13 "disappointing production in 2023," and it was disclosed that "Rivian's production
14 in 2024 would be even worse," resulting in Rivian's stock price "plummeting."
15 (FAC ¶ 2.) As to pleading falsity, "[a]lthough plaintiffs do not need to prove at
16 the pleading stage that [a] statement is false or misleading, pursuant to Rule 9(b)
17 and the PSLRA, they must plead with enough particularity to make the falsity or
18 the misleading character of the statement plausible." *In re NVIDIA Corp. Sec.*
19 *Litig.*, 2011 WL 4831192, at *4 (N.D. Cal. Oct. 12, 2011), *aff'd*, 768 F.3d 1046
20 (9th Cir. 2014); *see also Brown*, 875 F. Supp. 2d at 1112 (holding plaintiffs
21 sufficiently plead falsity in securities fraud action, noting defendant "essentially
22 disputes the accuracy of the conclusions" drawn from plaintiffs, which was
23 improper in a motion to dismiss challenging the sufficiency of plaintiffs'
24 complaint, reasoning "[i]f the allegations of the complaint are sufficiently
25 supported under the standard imposed by Rule 9(b) and the PSLRA, the fact that
26 the allegations may later be shown to be false or incorrect does not change that
27 fact or suggest that the case should not move beyond the pleadings stage").

28 Here, the FAC alleges Defendants' statements regarding positive statements

1 regarding demand, production, and the Roadmap were materially misleading
2 because Defendants knew at the time that:

- 3 1. “Rivian’s Backlog was based on fully refundable \$1,000
4 deposits that required no purchase commitment on the part of
5 the potential consumer, and could be canceled at any time for
any reason without penalty, which rendered the Backlog highly
volatile and unreliable” (FAC ¶ 137(a));
- 6 2. Rivian’s Backlog required consumers to wait extremely long
7 periods (approximately two years) before their turn came up to
8 purchase an EV, significantly increasing the risk of
cancellations, which, in turn, reduced the Backlog and the
supposed demand for Rivian EVs” (*id.* ¶ 137(b));
- 9 3. “A material portion of Rivian’s Backlog was based on pre-
10 March 1, 2022 preorders, which the Company committed to
11 fulfilling at an extremely low purchase price relative to cost,
undermining profitability and the rationale to ramp production
on the basis of those preorders.” (*id.* ¶ 137(c));
- 12 4. “Rivian’s support for claiming it had sufficient demand was
13 based on a highly unreliable Backlog that was volatile due to
14 the ease of cancellations, which Defendants watched closely”
(*id.* ¶ 143(b));
- 15 5. “Rivian’s cost to produce each EV, including bill of material
16 costs, and other fixed and variable costs associated with
operating the Normal Facility (below capacity), made the sale
17 of each EV highly unprofitable for the Company” and “[a]t the
time, Rivian lost tens of thousands of dollars on the sale of
each EV produced” (*id.* ¶ 143(e)); and
- 18 6. “Rivian was already experiencing supply chain, production,
19 and macroeconomic issues” (*id.* ¶ 143(f)).³

20 The FAC alleges each of the 32 challenged statements alleged are materially
21 misleading because (1) Defendants lacked a reasonable basis to assume there was
22 sufficient demand to warrant increased production or that produced units would be
23 sold at a profit as required to achieve gross-margin profitability in 2024; (2)
24 preorder backlog was not a reliable indicator of demand because preorders were
25 fully cancellable; (3) Rivian’s preorder backlog included a large number of pre-

26 ³ See also FAC ¶¶ 146, 151, 153, 156, 158, 160, 161, 163, 165, 167, 170, 173,
27 175, 177, 179, 181, 183, 186, 189, 191, 193, 195, 197, 199, 201, 204, 206
28 (alleging similar bases for why Defendants’ statements were materially misleading
as alleges in paragraphs 137 and 143 of the FAC).

1 March 1, 2022 preorders, which Rivian had committed to fulfilling at lower prices
2 that would undermine profitability; (4) macroeconomic factors, including rising
3 inflation and interest rates, were adversely affecting demand; and (5) Rivian was
4 experiencing supply chain and production issues that presented a challenge for
5 ramping production and achieving gross margin profits by 2024. (See FAC ¶¶ 5,
6 54, 141, 143, 163.) Accepting these allegations as true and in the light most
7 favorable to Plaintiff, the Court found in its MTD Order that Plaintiffs sufficiently
8 pled falsity because the statements created an impression of a state of affairs that
9 differed in a material way from what actually existed. (MTD Order at 5-6 (citing
10 *In re Quality Sys., Inc. Sec. Litig.*, 865 F.3d 1130, 1144 (9th Cir. 2017); *Glazer*
11 *Cap. Mgmt., L.P. v. Forescout Techs., Inc.*, 63 F.4th 747, 771 (9th Cir. 2023);
12 *Laborers Dist. Council Constr. Indus. Pension Fund v. Sea Ltd.*, 743 F. Supp. 3d
13 1083, 1106 (D. Ariz. 2024); *Stadium Cap. LLC v. Co-Diagnostics, Inc.*, 2024 WL
14 456745, at *6 (S.D.N.Y. Feb. 5, 2024); *San Antonio Fire & Police Pension Fund*
15 *v. Dentsply Sirona Inc.*, 732 F. Supp. 3d 300, 320 (S.D.N.Y. 2024).)

16 As to Defendants' contention that Plaintiffs' claims fail because all of the
17 issues were disclosed to the market, the Court found in its MTD Order that despite
18 Defendants' risk disclosures, "Plaintiffs plausibly allege Defendants made positive
19 statements about increases in demand based on the preorder Backlog which was
20 misleading to investors." (MTD Order at 6-7 (citing FAC ¶¶ 52, 136, 140, 142,
21 145-46, 150, 164-65; *Borteanu v. Nikola Corp.*, 2023 WL 1472852, at *11 (D.
22 Ariz. Feb. 2, 2023); *Farrar v. Workhorse Grp., Inc.*, 2021 WL 5768479, at *5
23 (C.D. Cal. Dec. 2, 2021); *Berson v. Applied Signal Tech., Inc.*, 527 F.3d 982, 987
24 (9th Cir. 2008); *In re Quality Sys., Inc. Sec. Litig.*, 865 F.3d at 1148).) In ruling
25 on Defendants' motion to dismiss, the Court considered Defendants' disclosures
26 (i.e., the "context" information which Defendants now contend are required to be
27 considered by a reasonable investor under *Sneed*), and found even considering
28 Defendants' disclosures, "Plaintiffs plausibly allege Defendants made positive

1 statements about increases in demand based on the preorder Backlog which was
2 misleading to investors,”⁴ and “Plaintiffs plead sufficient facts that these
3 statements regarding customer demand would be misleading to an investor where
4 Defendants omitted facts regarding the reliability of the Backlog as a basis for
5 demand.” (MTD Order at 6-7, 12.)⁵

6 Thus, even considering Defendants’ disclosures and the Ninth Circuit’s
7 *Sneed* decision, the Court cannot find as a matter of law that Defendants’ alleged
8 statements would not mislead a reasonable investor.

9 IV. CONCLUSION

10 Accordingly, the Court **DENIES** Defendants’ Motion for Judgment on the
11 Pleadings.

12 **IT IS SO ORDERED.**

13
14 DATED: January 22, 2026.


15 CONSUELO B. MARSHALL
16 UNITED STATES DISTRICT JUDGE

17
18 ⁴ The Court noted “the FAC alleges Defendants’ Roadmap for production was
19 “principally based” on a ‘backlog of preorders (the ‘Backlog’), which’ Defendants
20 ‘admittedly ‘closely watched – along with cancellation rates and macroeconomic
21 factors – ‘daily,’ and starting in November 2022, ‘Defendants stopped reporting
22 Rivian’s Backlog to the public’ and ‘never reported Rivian’s cancellation rates.’
23 (FAC ¶ 5.) Therefore, the FAC identifies the Backlog regarding preorders which
24 Defendants stopped reporting publicly.” (MTD Order at 5.) Moreover, the Court
noted “the FAC identifies the Backlog as the metric which Defendants stated they
reviewed ‘daily,’ and which is the data Plaintiffs contend Defendants materially
misrepresented to investors. (See FAC ¶¶ 2, 5, 53, 91, 123, 182.)” (MTD Order
at 12.) Thus, while Defendants made certain risk disclosures about the Backlog,
Defendants stopped publicly reporting Backlog preorders but allegedly made
statements regarding increases in demand based on the preorder Backlog that
Plaintiffs plausibly allege were misleading to a reasonable investor.

25 ⁵ Plaintiffs argue Defendants’ Motion was filed to unduly delay discovery and is
26 an untimely motion for reconsideration. There is nothing in the record clearly
27 demonstrating the Motion was filed for an improper purpose. Regardless of
28 whether the Court treats the instant Motion as a motion for judgment on the
pleadings or a motion for reconsideration under L.R. 7-18, the Court denies the
Motion because even if the Court considers *Sneed*, Defendants fail to demonstrate
Defendants’ alleged statements would not mislead a reasonable investor as a
matter of law.